FAP-activated Capecitabine
/ Avacta
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 10, 2022
Capecitabine Plus Temozolomide vs Temozolomide Alone in Advanced Pancreatic Neuroendocrine Tumors
(THE ASCO POST)
- "In the updated final analysis of the phase II ECOG-ACRIN E2211 trial, patients with advanced pancreatic neuroendocrine tumors experienced a significant improvement in progression-free survival with capecitabine plus temozolomide over temozolomide alone.1 Although the 5-month difference in overall survival was not statistically significant, it was 'clinically meaningful,' according to Pamela L. Kunz, MD..."
Media quote
1 to 1
Of
1
Go to page
1